Objective. The aim of the present study was to investigate the associations of cumulative inflammatory burden (assessed by serial measurements of inflammatory markers) and classical cardiovascular disease (CVD) risk factors with asymmetric dimethylarginine (ADMA) in a large prospective cohort of patients with established RA.
Introduction
RA is associated with an increased incidence of atherothrombotic cardiovascular events that contribute to premature mortality compared with the general population [1, 2] . The inflammatory processes in the rheumatoid synovium and atherosclerotic plaques are remarkably similar, suggesting that RA disease-related inflammation might contribute to the excess cardiovascular risk [3] . Several lines of evidence support the presence of subclinical cardiovascular disease (CVD) in RA, with significantly impaired endothelial function-the initial step of atherogenesis-and abnormal vascular morphology relative to healthy controls [4] .
A healthy endothelium maintains an atheroprotective environment within the vessel by enabling the constitutive production of nitric oxide (NO), a free radical with antiinflammatory, anti-thrombotic and anti-apoptotic properties. It is thought that dysregulation of NO metabolism plays a central role by promoting endothelial injury, which may in turn initiate coagulation abnormalities, platelet activation, local expression of adhesion molecules and inflammatory mediators, as well as lipid disorders, all of which have been well described in patients with RA [57] .
Asymmetric dimethylarginine (ADMA) is a non-selective endogenous inhibitor of the three isoforms of NO synthase and has emerged as a novel risk factor for vascular disease. Higher ADMA levels have been reported in various disease subsets characterized by atherosclerosis and endothelial dysfunction, including patients with established classical CVD risk factors, peripheral vascular disease and chronic kidney disease [8] . More importantly, observations from large longitudinal cohort studies indicate that elevated ADMA levels may predict future CVD events and death both in the general population and in individuals suffering from various pathological conditions [914] . RA is associated with excess CVD risk that is comparable to that of diabetes, and it is has been suggested that the reduced bioavailability of NO may accelerate atherosclerosis in RA [4] . Thus assessment of ADMA could provide early information on alterations in NO biology and subsequent CVD risk in RA.
In patients with RA, ADMA levels are elevated compared with age-and sex-matched controls [1517] , but the precise mechanisms for this are unclear. It is possible that RA disease-related inflammation may contribute to elevated ADMA levels in RA, but the relationship between ADMA and markers of systemic inflammation has been an issue of debate, as cross-sectional studies have provided conflicting results. For example, Kwasny-Krochin et al.
[18] demonstrated positive correlation between oxidative stress and CRP in 46 RA patients with active disease while other studies failed to establish such association [15, 19, 20] . However, most of the studies have only included a single measurement of inflammatory markers, which may not accurately represent cumulative inflammatory burden. It has been hypothesized that the inflammatory load over a longer period of time could have a larger impact on the endothelium and the subsequent development of atherosclerosis in chronic high-grade systemic inflammatory disorders such as RA [21] . To our knowledge, there are no studies that have assessed the long-term effects of inflammation or classical CVD risk factors on ADMA in RA.
The aim of the present study was to investigate whether cumulative systemic inflammatory burden and/or highly prevalent classical CVD risk factors in RA associate with circulating ADMA levels in a large well-characterized cohort of patients with long-standing RA.
Methods

Participants
Four hundred consecutive RA patients were recruited from the rheumatology outpatient clinics of the Dudley Group NHS Foundation Trust (UK) in 2006. The patients were part of the Dudley Rheumatoid Arthritis Co-morbidity Cohort (DRACCO), a prospective study examining CVD burden in RA. Detailed characteristics of these patients have been reported previously [22] . Since the initiation of the study, 78 patients have died from various causes (cardiac and non-cardiac). The remaining 322 were asked to return for a follow-up visit in 2012. One hundred and twenty-one patients declined to take part for various personal reasons, so 201 patients took part in the follow-up study and only the baseline data (2006) from these patients are reported in this article. All patients met the 1987 ACR revised RA criteria [23] . The study received ethics approval from the Black Country Research Ethics Committee. All participants gave their written informed consent according to the Declaration of Helsinki.
Protocol for baseline visit
All patients reported to the clinical research facility after a 12 h overnight fast and underwent a thorough baseline evaluation, including a detailed review of their medical history and hospital records, physical examination and contemporary assessments of height, weight, BMI, body composition (using a BC-418 Body Composition Analyser; Tanita, Tokyo, Japan), current 28-joint DAS (DAS28) [24] and physical function using the HAQ [25] . The Framingham Risk Score and Reynolds Risk Score were calculated as previously described [26] . All medications and their indications were recorded. Venous blood was collected on the same day and a wide range of tests was performed. Biochemical and haematological estimations included fasting lipids, complete serum biochemistry, fasting glucose, fasting insulin, CRP and ESR. Insulin resistance (IR) was assessed by calculating the Homeostasis Model Assessment IR (HOMA-IR) and Quantitative Insulin Sensitivity Check Index, as previously described [27, 28] . All biochemical tests were carried out in the Biochemistry Laboratory at Russells Hall Hospital, Dudley Group NHS Foundation Trust, UK.
Protocol for follow-up visit
Patients reported to the same clinical research facility as in the baseline assessment in 2012 after a 12 h overnight fast. A venous blood sample was collected to assess ADMA levels. ADMA levels were measured in serum samples using a commercial enzyme immunoassay ELISA kit (Immundiagnostik, Bensheim, Germany) as previously described [15] . The intra-assay coefficient of variation was 7.6%.
Cumulative inflammatory burden
Detailed information on inflammatory markers (CRP and ESR) from the baseline visit to the follow-up visit for each patient was used to calculate the cumulative inflammatory burden. A quarterly measurement of CRP and ESR for each year the patient was in the study was used to calculate the area under the curve (AUC) for each parameter.
ESR was measured using the StaRRsed Auto Compact blood sedimentation instrument (Mechatronics, Zwaag, The Netherlands), which automatically carries out the ESR analysis according to the Westergren reference method.
CRP was measured using the VITROS 5,1 FS Chemistry System (Ortho-Clinical Diagnostics, Rochester, NY, USA). This is an immunoturbidimetric method. The antibody in the reagent combines with CRP in the specimen, thereby increasing turbidity in the solution. This is measured as an increase in absorbance at 340 nm.
Statistical analysis
ADMA values were compared between the levels of binary categorical variables (CVD risk factors) using MannWhitney tests, or JonckheereTerpstra tests where there were multiple ordinal categories. AUCs for the ESR and CRP data were calculated for the quarterly measurements made between 2006 and 2012. Since some patients had missing data at the start or end of the period, the AUCs were dependent on the length of time the data were available. For this reason, the resulting AUCs were divided by the total period that data were available for each patient to produce average AUCs (AAUCs).
Prior to the analysis, the ESR, CRP and ADMA values were log 2 -transformed in order to reduce the level of skew in the distributions. Univariable regression models were then produced in order to test the ability of the ESR and CRP values to predict ADMA. Multivariable models were also produced for both of these factors, which also included a range of classical and disease-related CVD risk factors, i.e. hypertension, dyslipidaemia, obesity, IR, smoking status, diabetes, ACPAs and Framingham risk category. These models were used to test whether the effect of ESR/CRP on ADMA was independent of CVD risk factors. The coefficients from the models were then anti-logged, with the resulting values representing the percentage increase in ADMA associated with a 2-fold increase in the factor.
Associations between ADMA and contemporary measurements of inflammation and classical CVD risk factors were performed using linear and binary logistic regression for continuous and categorical data, respectively. All analyses were performed using SPSS 19 (IBM, Armonk, NY, USA), with P < 0.05 deemed to be indicative of statistical significance.
Results
Baseline characteristics
All 201 patients successfully underwent assessment at both time points. Table 1 displays the patient characteristics. The majority of patients were female with moderate to high disease activity at baseline, but with lower disease activity during follow-up.
CVD risk factors and ADMA Table 2 Adjustment for the effects of classical CVD risk factors in a multivariable model had a minimal effect on the modelled relationships between the inflammatory factors and ADMA, with all factors that were significant in univariable analysis remaining significant in the multivariable model (Table 3) .
Discussion
The most salient finding of our study is the establishment of a doseresponse relationship between current and cumulative inflammatory burden with ADMA levels in a large number of patients with RA. This relationship was independent of classical CVD risk factors. These results expand the current knowledge on the association between chronic inflammation and increased production of ADMA in patients with RA.
The majority of CVD events occur in RA patients with high disease activity [29] and the pathogenic role of CRP and several soluble inflammatory mediators to vascular function have been extensively investigated in recent years [30] . However, a systematic review of both crosssectional and longitudinal studies did not support a direct association between disease-related inflammation and changes in non-invasive assessments of peripheral vascular function and morphology in RA [4] . One important limitation of non-invasive assessments of the vasculature is the high degree of operator dependency, thus other tools, such as biochemical markers, which are less susceptible to this type of variability, have been utilized as an alternative approach to investigating vascular pathology.
Circulating ADMA levels have been linked to increased CVD risk. Experimental studies in animal models have demonstrated that ADMA synthesis is up-regulated and degradation is attenuated by inflammatory activity, suggesting a close relationship between inhibition of the NO pathway and systemic inflammation, with TNF-a playing a crucial role. [31, 32] . Although the causality of such an association has not been proved in humans, previous studies have demonstrated that ADMA is rapidly elevated in response to acute inflammation in healthy individuals [33] and is associated with low-grade systemic inflammation in population-based studies [34] . It has been suggested that oxidative stress-induced inactivation of dimethylarginine dimethylaminohydrolase-the enzyme that hydrolyses ADMA to L-citruline and dimethylamine-is the mechanism most likely to be involved in the accumulation www.rheumatology.oxfordjournals.org of ADMA, particularly in low-grade inflammatory conditions [34] .
Oxidative stress and inflammatory markers have been correlated with elevated ADMA concentrations in patients with RA, implying that ADMA may contribute to the vascular injury observed in this condition [1618] . However, such relationships have not been confirmed in other crosssectional cohorts [15, 19] , while some recently published longitudinal studies have shown that ADMA levels remain unchanged after treatment with TNF-a inhibitors despite adequate control of clinical or serological inflammation [20, 35, 36] . A limitation of the majority of published studies is the inclusion of small heterogeneous samples, diverse study designs and outcome measures and varying inclusion criteria regarding pre-existing CVD risk factors, duration of RA, disease activity levels and treatment.
Against this background of uncertainty, our study assessed-for the first time-the effect of cumulative inflammatory burden on ADMA in a large population of RA patients with well-established disease. Since RA is a chronic relapsing condition with inflammatory fluctuations over a period of time, a single measurement of inflammatory markers may not be able to estimate the total cumulative inflammatory burden to which an individual has been exposed. Patients with longer periods of uncontrolled disease are more likely to develop endothelial dysfunction due to the higher cumulative inflammatory burden on the vasculature [37] . Thus the characterization of cumulative inflammatory load may be a more important determinant of the progression of vascular damage than inflammation measured at a single time point [21] . In this regard, our results suggest that ADMA may have a role in the development of inflammation-related endothelial dysfunction in RA over a protracted time scale, although it is clear that such statistical associations do not necessarily prove a causeeffect relationship.
ADMA has been described as a mediator of endothelial dysfunction in several conditions associated with atherosclerosis, such as dyslipidaemia, hypertension, peripheral arterial disease and chronic kidney disease [38] . IR was the only independent predictor of elevated ADMA levels in 67 RA patients, while other CVD risk factors did not appear to have any effect [39] . In the current study, elevated ADMA levels were independent of all CVD risk factors including IR and were also not related to CVD risk prediction scores, although their usefulness in predicting CVD risk in RA is under consideration [40] . In line with our observations, other studies in patients with coronary artery disease [41] and cerebrovascular disease [42] have also reported no association between ADMA and traditional CVD risk factors. However, the association between ADMA and IR remains to be determined, as other reports have been inconclusive [43, 44] . For example, a recent study showed that ADMA predicts future deterioration of glucose tolerance in male patients with stable coronary artery disease independently of baseline glucose sensitivity [45] . Given that IR and RA share similar atherogenic processes such as the acute phase response and endothelial dysfunction, these results may suggest a bidirectional influence between ADMA and impairment of glucose tolerance, in turn providing an additional explanation for the impact of low-and high-grade chronic inflammation on ADMA. The relationship between classical CVD risk factors, RA-related inflammation and endothelial dysfunction remains unclear. Inflammation appears to play a pivotal role in the sequence of events leading to CVD events and also appears to alter the activity of classical CVD risk factors, which, relative to the general population, have a different risk profile in RA [46] . In that respect, our results concur with previous studies exploring the association between cumulative inflammation and subclinical atherosclerosis in RA, which have demonstrated positive b Represents the increase in ADMA for a 2-fold increase in the factor. *Significant at P < 0.05. ADMA: asymmetric dimethylarginine; AAUC: average area under the curve.
www.rheumatology.oxfordjournals.org correlations between cumulative ESR inflammatory load and arterial stiffness, but no relationship with classical CVD risk factors [47] .
We acknowledge that the findings of the current study partially contrast with the conclusion of our recently published systematic review, which failed to establish robust correlations between systemic inflammation and non-invasive assessments of vascular function and morphology [4] . However, this discrepancy may reflect differences in the various methods of investigating endothelial function, as ADMA is a biochemical marker with no known specificity for the microvasculature or macrovasculature. It is worth noting that ADMA level, even if elevated, does not seem to be a straightforward indicator of vasodilatory endothelial dysfunction in rheumatic diseases, as demonstrated by the lack of correlation between ADMA and flow-mediated dilation of the brachial artery in AS [48] and micro-and macrovascular endothelial function in RA [15] . In addition, biologic treatment appears to have little impact on ADMA in RA patients despite improvements in parameters of endothelial function such as coronary flow reserve [49] .
ADMA has been established as an independent predictor of mortality in coronary artery disease [13], a condition that represents the leading cause of CVD death in RA. To the best of our knowledge, the prognostic value of ADMA on CVD events and deaths in large prospective studies in patients with RA has not been examined. On the other hand, several findings suggest that ADMA contributes directly to oxidative stress by causing endothelial NO synthase uncoupling and leading to the generation of superoxide [50] . Thus ADMA may be characterized as a pro-inflammatory mediator of vascular injury, which highlights the importance of assessing ADMA levels in chronic inflammatory diseases. Further research is required to help delineate the mechanisms responsible for accumulation of ADMA in RA, as this will provide a greater understanding of the role of NO biology in RA-mediated accelerated atherosclerosis. Ideally, such studies will need to be performed in large cohorts of patients and focus on specific cardiac endpoints. Studies targeting interventions that reduce ADMA could help improve CVD risk and outcomes in this population.
The major limitation of the present study is the absence of serial measurements of ADMA, as circulating levels of the biomarker may fluctuate from time to time. However, it is plausible that high levels of cumulative inflammation activate mechanisms that result in chronically elevated ADMA in the circulation, leading to endothelial dysfunction. Unfortunately we did not have the data to adjust for cumulative exposure to anti-rheumatic drugs, but longitudinal studies have shown that specific RA-related treatments do not affect ADMA levels [20, 35, 36] . We also included patients with co-morbidities and various CVD risk factors, as we aimed to assess a real-life population. Our study contains adequate assessment and measurement of classical CVD risk factors at baseline. To the best of our knowledge, this is the largest study investigating the role of ADMA in RA and our population is representative of the wide spectrum of RA patients attending routine rheumatology clinics.
In summary, we demonstrated that cumulative inflammatory burden is associated with ADMA levels in RA. Our results suggest that the level of inflammatory burden and biochemical impairment in the vasculature are closely interrelated in RA, indicating a potential pathway for diminished NO bioavailability and endothelial dysfunction in this population. However, the causal relationship between ADMA and CVD in RA remains to be determined in large population-based studies that will move beyond associations and investigate the robustness of ADMA as a noninvasive surrogate risk factor for CVD events and death.
Rheumatology key messages
. Asymmetric dimethylarginine is a novel marker of cardiovascular disease morbidity with a potential pro-inflammatory action on the vasculature. . Cumulative inflammatory burden is associated with asymmetric dimethylarginine in patients with RA. . The role of asymmetric dimethylarginine as part of a multimarker cardiovascular disease risk tool needs to be investigated.
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